Biomarker & Intervention Discovery
Lyme Disease / Post-Treatment Lyme Disease Syndrome (PTLDS)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$54MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionAcute Lyme: spontaneous resolution in some untreated patients but dissemination and late manifestations develop; PTLDS…
Best-intervention remissionAcute Lyme: 14-21 day doxycycline achieves 80-95% cure; PTLDS: no treatment shown superior to placebo in 4 large RCTs…
Gap sizeLarge for PTLDS — the field lacks an evidence-based treatment and has been mired in controversy over mechanism and…
Primary barrierbiological (PTLDS mechanism uncertain) + framing (controversy)
Full remission profile →
Remission & chronicity
Spontaneous remission
Acute Lyme: spontaneous resolution in some untreated patients but dissemination and late manifestations develop; PTLDS (persistent symptoms after adequate antibiotics): affects 10-20% of patients; spontaneous resolution of PTLDS in 50-60% by 6 months
Best-intervention remission
Acute Lyme: 14-21 day doxycycline achieves 80-95% cure; PTLDS: no treatment shown superior to placebo in 4 large RCTs; prolonged antibiotic therapy (IDSA-condemned) not effective; symptom management only
Gap size
Large for PTLDS — the field lacks an evidence-based treatment and has been mired in controversy over mechanism and management
Primary barrier
biological (PTLDS mechanism uncertain) + framing (controversy)
PTLDS treatment is one of the most contentious areas in medicine; IDSA position (no benefit of prolonged antibiotics) vs ILADS position (chronic infection requiring extended treatment) — RCTs support IDSA; the patient experience of persistent symptoms is real but the mechanism may not be ongoing active infection; this creates a significant care gap for suffering patients
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Lyme Disease / Post-Treatment Lyme Disease Syndrome (PTLDS)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."